论文部分内容阅读
目的:观察瑞舒伐他汀联合心血通胶囊预防冠状动脉支架术后再狭窄的临床疗效。方法:将120例冠状动脉支架术后患者随机分为2组各60例,对照组予西医常规治疗加瑞舒伐他汀和安慰剂,治疗组予西医常规治疗加瑞舒伐他汀和心血通胶囊,2组均治疗6月。治疗结束后复查冠脉造影,观察比较2组患者的冠状动脉支架再狭窄率、血脂和超敏C-反应蛋白(hs-CRP)水平变化。结果:冠状动脉支架术后再狭窄率对照组13.33%,治疗组3.33%,2组比较,差异有统计学意义(P<0.05)。治疗后2组血脂水平比较,差异均无统计学意义(P>0.05);治疗后,2组总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)水平均较治疗前明显下降(P<0.05)。治疗前2组hs-CRP比较,差异无统计学意义(P>0.05)。治疗后,2组hs-CRP水平均较治疗前下降,差异有统计学意义(P<0.05);治疗组hs-CRP水平低于对照组(P<0.05)。结论:瑞舒伐他汀联合心血通胶囊可显著改善冠状动脉支架术后再狭窄,有效抑制炎症。
Objective: To observe the clinical efficacy of rosuvastatin combined with Xuesantong capsule in preventing restenosis after coronary stenting. Methods: A total of 120 patients undergoing coronary stenting were randomly divided into two groups (n = 60 in each group). The control group was treated with routine western medicine plus rosuvastatin and placebo. The treatment group was treated with routine western medicine plus rosuvastatin and xuesantong capsule , Two groups were treated in June. Coronary angiography was performed after the end of treatment. The coronary stent restenosis rate, serum lipids and hs-CRP levels were compared between the two groups. Results: The rate of restenosis after coronary stenting was 13.33% in the control group and 3.33% in the treatment group. There was significant difference between the two groups (P <0.05). After treatment, the levels of total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) were significantly decreased in both groups (P> 0.05) after treatment <0.05). There was no significant difference in hs-CRP between the two groups before treatment (P> 0.05). After treatment, the levels of hs-CRP in both groups decreased compared with those before treatment, with significant difference (P <0.05). The hs-CRP level in the treatment group was lower than that in the control group (P <0.05). Conclusion: Rosuvastatin combined with Xuesantong Capsule can significantly improve restenosis after coronary stent implantation and effectively inhibit inflammation.